A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

Summary

This is a three-part Phase 2a study. The aim of Part A is to assess the safety and tolerability and preliminary antidepressant efficacy in patients with MDD who are not currently on an antidepressant therapy. The aim of Part B is to assess the antidepressant efficacy, safety and tolerability in patients with MDD who are partial responders while on a current and adequate single SSRI or SNRI treatment. Part C aims to replicate the monotherapy findings of Part A, but with a lower control group dose.

Timeline

Start

2024-01-31

Primary completion

2026-10

Completion

2026-10

Drugs

Indications